THORACIC SURGERY ONCOLOGY GROUP NEWS Spring 2026

A collaboration between AATS and Memorial Sloan Kettering Cancer Center

FROM THE TSOG CHAIR

In this issue, we will take a look at TSOG's growth in its sites and clinical trial portfolio, which includes 11 trials. TSOG has expanded to include 38 sites in total, welcoming new locations University of Rochester (PI, Paul Feingold, MD), Cedars-Sinai Medical Center (PI, Harmik Soukiasian, MD), Hartford HealthCare (PI, Brian Whang, MD), The University of Alabama at Birmingham (PI, James Donahue, MD), The University of Arizona (PI, Stephanie Worrell, MD), University of California San Diego (PI, Mark Onaitis, MD), and University of Texas Southwestern Medical Center (PI, Inderpal Sarkaria, MD). Since our last issue, the following TSOG studies have closed to enrollment: TSOG 101 ctDNA study (PI, James M. Isbell, MD, MSCI), TSOG 104 FBLN3 Mesothelioma study (PI, Harvey Pass, MD), TSOG 105 SORT study (PI, Benjamin Kozower, MD), and TSOG 109 TL-12 study (PI, David R. Jones, MD). TSOG's 2025 annual meeting was in Boston in September 2025. Our next meeting will be in NYC in September 2026. Collaborative discussions took place among TSOG Site Investigators and Coordinators in Boston about the current TSOG portfolio and paths for moving the group forward. Continued progress, including transatlantic cooperation with the European Society of Thoracic Surgeons new clinical trials group (TEST) on the TSOG 108 segmentectomy study—a first for thoracic surgeons—has been made. Discussed later in the newsletter is TSOG's commitment to providing quality data on all of the TSOG protocols. Amendment number 2 to the TSOG Consortium Agreement, which addresses the use and ownership rights of data and publications, has been signed by nearly all 38 sites. Finally, TSOG has grown its presence on social media since our last newsletter, with active participation on X, continued updates on the TSOG website, and the release of the TSOG video.

—David R. Jones, MD

IN THIS ISSUE

New TSOG Trials
Page 2

Update on Current TSOG Trials
Page 3

Data Quality and TSOG in 2026
Page 5

New TSOG Trials

TSOG 110

James M. Isbell, MD, MSCI, from Memorial Sloan Kettering Cancer Center, is the lead PI for TSOG 110, "Phase II trial of neoadjuvant trastuzumab deruxtecan for patients with stage II-III HER2-amplified or HER2-mutated non-small cell lung cancer (HERCULES)." This study is receiving funding from AstraZeneca and will evaluate response rates to neoadjuvant trastuzumab deruxtecan in resectable HER2-mutated or -amplified, clinical stage II-III NSCLC. The study is open to accrual at MSK as of February 2026, with activation underway, and is being explored at interested TSOG sites. Contact Chaya Friedman, Memorial Sloan Kettering Research Program Manager, at friedmc1@mskcc.org if your site is interested in participating in the study.

TSOG 111

"Multicenter randomized phase II trial of neoadjuvant radioimmunotherapy versus chemoimmunotherapy in patients with clinical stages IB-III (N2) non-small cell lung cancer" is led by PI Nasser Altorki, MD, from Weill Cornell Medicine. This study is receiving funding from Regeneron and is in the process of activating at selected TSOG sites. The trial is open to accrual at Weill Cornell Medicine (February 2025) and MSK (March 2026). The study's primary objective is to determine whether neoadjuvant SBRT combined with cemiplimab (PD1 inhibitor) is associated with a higher rate of pathological response, compared with chemotherapy plus cemiplimab.

Update on Current TSOG Trials

TSOG 101 ctDNA Study

Led by James M. Isbell, MD, MSCI, from Memorial Sloan Kettering Cancer Center, TSOG 101 opened in 2019. The study closed to accrual at all 15 sites August 2025. As of May 2026, 102 patients are on study across all sites. Since the study's activation at the site in June 2021, Centre Hospitalier de l'Université de Montréal has accrued 39 patients and continues to maintain the title as the second highest accruing site (PI, Moishe Liberman, MD). The study was amended in 2024 to allow Foresight Diagnostics to analyze samples. The samples are now being processed for ctDNA analysis.

TSOG 102 GGO Trial

Closed to accrual in December 2023, led by James Huang, MD, TSOG 102 reached its target accrual (N=330). Twenty-one TSOG sites across North America accrued patients to this trial. This was the first clinical trial for which TSOG reached target accrual; it will continue to follow patients per the protocol for up to 5 years. Fifty percent of patients will complete the study by the end of 2026. Dr. Huang provided a brief invited commentary to *JTCVS* on behalf of TSOG about the completion of accrual for TSOG 102, available here.

TSOG 103 Colorectal Metastases Trial

Since Fall 2023, this study, led by Mara Antonoff, MD, from MD Anderson Cancer Center, remains closed to accrual, with 38 patients on study being followed up for survival. Dr. Antonoff presented a comprehensive abstract at the 2025 AATS International Thoracic Surgical Oncology Summit. This abstract, titled "Outcomes and lessons learned from TSOG 103: Multimodality management in risk-stratified patients with lung-limited metastatic colorectal cancer," represents the culmination of TSOG's collaborative efforts and data gathered through the study. The manuscript was published in *JTCVS Open* in April 2026.

TSOG 104 FBLN3 Mesothelioma Study

This study, led by Harvey Pass, MD, of the New York University Langone Medical Center, closed to accrual in March 2025. The study activated at New York University in June 2021 and includes 5 additional participating TSOG sites: University Health Network (study PI, Marc De Perrot, MD), Baylor College of Medicine (study PI, Robert Taylor Ripley, MD), Brigham and Women's Hospital (study PI, Raphael Bueno, MD), Duke University (study PI, David Harpole, MD), and Memorial Sloan Kettering Cancer Center (study PI, Prasad S. Adusumilli, MD). The study collected nearly 100 blinded mesothelioma samples from the TSOG external sites. Analysis started in September 2025 and is complete. As of February 2026, the study is closed at all sites.

TSOG 105 SORT Study

This study, led by Benjamin Kozower, MD, from Washington University, opened to accrual at 8 TSOG and non-TSOG sites, with the first site activation at Washington University in 2022. The June 2025 study amendment provided a 2:1 allocation between surgery and SBRT, with the hopes of bringing the study closer to reaching the target accrual for each cohort in a short amount of time. The surgery arm reopened to accrual after reaching target accrual in April 2024. Recruitment closed in March 2026. The study has 446 patients on study at all sites, which is an increase of 257 since November 2023. Since the study's activation in July 2022, Washington University leads accrual with 211 patients on study, followed by MD Anderson Cancer Center and MSKCC, which each has 56 patients on study since activation in November 2022.

TSOG 107 Lymph Node Dissection Study

Paula Ugalde, MD, from Brigham and Women's Hospital (BWH), leads TSOG's first BWH-initiated study. The primary objective of this study is to compare the number of stations and lymph node samples acquired when adopting a standardized technique, compared with the conventional (previous) technique. As of June 2026, TSOG 107 is open to accrual at BWH, MSK (study PI, Katherine D. Gray, MD), The University of Michigan (study PI, Jules Lin, MD), Allegheny Health Network (study PI, Benny Weksler, MD), and Baylor College of Medicine (study PI, Ramiro Fernandez, MD), with a total of 62 patients on study and a target of 160 at all TSOG sites. The study is in the process of activating at 3 additional TSOG sites: Centre Hospitalier de l'Université de Montréal (study PI, Moishe Liberman, MD), Massachusetts General Hospital (study PI, Michael Lanuti, MD), and University Health Network/University of Toronto (study PI, Kazuhiro Yasufuku, MD).

TSOG 108 Segmentectomy Study

TSOG Executive Board Chair David R. Jones, MD, from Memorial Sloan Kettering Cancer Center, leads this international registry with the primary objective of determining 3- and 5-year disease-free survival among patients undergoing pulmonary segmentectomy for clinical stage I cancer. As of May 2026, TSOG 108 is open to accrual at 13 TSOG sites, with 13 sites either in the process of activation or interested in participating in the trial. Current top accruing sites, in addition to MSK (activated May 2024), include The University of Michigan (activated May 2025; study PI, Jules Lin, MD), University Health Network (activated July 2025; study PI, Elliot Wakeam, MD), and Centre Hospitalier de l'Université de Montréal (activated December 2025; study PI, Moishe Liberman, MD). At present, 123 patients are on study. Target accrual is 600 patients. The study team is working with Thoracic European Surgical Trials (TEST), the clinical trials platform of the European Society of Thoracic Surgeons, to activate the study with our European colleagues. TEST has 15 sites on board for TSOG 108 so far. The team is moving forward with regulatory and database tasks related to study rollout.

TSOG 109 TROPION-Lung12

Led by David R. Jones, MD, from Memorial Sloan Kettering, TL-12 is an industry-sponsored study with AstraZeneca. TSOG 109 will seek to demonstrate the superiority of adjuvant Dato-DXd in combination with rilvegostomig, compared with the standard of care, after complete tumor resection. Assessment of disease-free survival using blinded independent central review will be performed among participants with stage I adenocarcinoma NSCLC who are ctDNA positive or have at least 1 high-risk pathological feature. Fourteen TSOG sites opened this study to accrual. As of the December 2025 TL-12 study newsletter, 72 sites in the United States and Canada have been activated. Centre Hospitalier de l'Université de Montréal (study PI, Moishe Liberman, MD) is the only TSOG site to randomize a patient on this trial, which closed to enrollment on December 22, 2025, because of significant enrollment challenges.

Data Quality for TSOG Protocols

TSOG sites have identified several strategies for improving data entry and protocol compliance for TSOG studies, including monthly communications of task lists and expected data entry timelines, REDCap queries for discrepant or missing data, and monthly assessment of regulatory binder items. When applicable to a TSOG study, payment for visit time points contingent on completed data entry has been found to be beneficial. Annual audits have proved to be productive for some TSOG protocols. Post-audit meetings are held with the Site Coordinator(s) to discuss any major findings or recurrent issues. In certain cases, the site PI may be asked to attend these meetings to clarify particular workflow and/or clinical questions, as well as minimize the back and forth between PI and coordinators. Finally, feedback from audits has helped identify areas of confusion, prompted further discussions across the larger group of site teams, and has even led to amendments to protocol documents to clarify ambiguities. In 2025, a total of about 30 audits were conducted for TSOG 101 ctDNA, 102 GGO, 103 Colorectal Metastases, and 108 Segmentectomy trials. NYU completed quality reviews of informed consent forms for TSOG 104 FBLN3 Mesothelioma trial participating sites. WUSTL continues conducting regular queries through REDCap to reconcile data and/or documentation issues for TSOG 105 SORT study.

TSOG in 2026

The 2026 TSOG Annual Meeting will be held at the Sheraton New York Times Square Hotel in New York City on September 24, 2026, ahead of the International Thoracic Surgical Oncology Summit (ITSOS), also at the same location on September 25 to 26. Come and visit the TSOG booth during ITSOS.